Point72 Asia (Singapore) Pte. Ltd. Athira Pharma, Inc. Transaction History
Point72 Asia (Singapore) Pte. Ltd.
- $480 Billion
- Q2 2024
Shares
2 transactions
Others Institutions Holding ATHA
# of Institutions
74Shares Held
22.8MCall Options Held
73.4KPut Options Held
97.8K-
Perceptive Advisors LLC New York, NY5.4MShares$2.32 Million0.41% of portfolio
-
Baker Bros. Advisors LP New York, NY3.15MShares$1.36 Million0.11% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.63MShares$702,8060.0% of portfolio
-
Propel Bio Management, LLC Los Angeles, CA1.49MShares$641,9002.57% of portfolio
-
Simplify Asset Management Inc. New York, NY1.49MShares$641,9000.29% of portfolio
About Athira Pharma, Inc.
- Ticker ATHA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 37,817,700
- Market Cap $16.3M
- Description
- Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical tri...